• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Med Virol . WHOLE-GENOME SINGLE MOLECULE REAL-TIME SEQUENCING OF SARS-CoV-2 OMICRON

tetano

Editor, Senior Moderator
J Med Virol


. 2023 Feb 9.
doi: 10.1002/jmv.28564. Online ahead of print.
WHOLE-GENOME SINGLE MOLECULE REAL-TIME SEQUENCING OF SARS-CoV-2 OMICRON


Florence Nicot[SUP] 1 [/SUP], Pauline Trémeaux[SUP] 1 [/SUP], Justine Latour[SUP] 1 [/SUP], Romain Carcenac[SUP] 1 [/SUP], Sofia Demmou[SUP] 1 [/SUP], Nicolas Jeanne[SUP] 1 [/SUP], Noémie Ranger[SUP] 1 [/SUP], Clémentine De Smet[SUP] 1 [/SUP], Stéphanie Raymond[SUP] 1 2 [/SUP], Chloé Dimeglio[SUP] 1 2 [/SUP], Jacques Izopet[SUP] 1 2 [/SUP]



Affiliations

Abstract

New variants and genetic mutations of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) genome can only be identified using accurate sequencing methods. Single molecule real-time (SMRT) sequencing has been used to characterize Alpha and Delta variants, but not Omicron variants harbouring numerous mutations in the SARS-CoV-2 genome. This study assesses the performance of a target capture SMRT sequencing protocol for whole genome sequencing (WGS) of SARS-CoV-2 Omicron variants and compared it to that of an amplicon SMRT sequencing protocol optimized for Omicron variants. The failure rate of the target capture protocol (6%) was lower than that of the amplicon protocol (34%, p<0.001) on our dataset, and the median genome coverage with the target capture protocol (98.6% [IQR: 86-99.4]) was greater than that with the amplicon protocol (76.6% [IQR: 66-89.6], (p<0.001)). The percentages of samples with >95% whole genome coverage were 64% with the target capture protocol and 19% with the amplicon protocol (p<0.05). The clades of 96 samples determined with both protocols were 93% concordant and the lineages of 59 samples were 100% concordant. Thus, target capture SMRT sequencing appears to be an efficient method for WGS, genotyping and detecting mutations of SARS-CoV-2 Omicron variants. This article is protected by copyright. All rights reserved.

Keywords: Omicron; SARS-CoV-2 genotyping; SMRT sequencing; long read sequencing; whole genome sequencing.
 
Back
Top Bottom